Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.

Douglas Lorne ArnoldBrenda BanwellAmit Bar-OrAngelo GhezziBenjamin M GreenbergEmmanuelle WaubantGavin GiovannoniJerry S WolinskyJutta GärtnerKevin RostásyLauren KruppMarc TardieuWolfgang BrückTracy E StitesGregory L PearceDieter A HäringMartin MerschhemkeTanuja Chitnisnull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2020)

Fingolimod significantly reduced MRI activity and ARBA for up to 2 years versus IFN β-1a in PoMS.

Keyphrases

multiple sclerosis
contrast enhanced
magnetic resonance imaging
white matter
diffusion weighted imaging
emergency department
immune response
computed tomography
dendritic cells
type diabetes
magnetic resonance
insulin resistance
skeletal muscle
weight loss
glycemic control